Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

North American Buyers Turn to European Branded Generics For Growth

Executive Summary

Europe's tough pricing and reimbursement environment may make it a graveyard for growth in innovative drugs, but there's still plenty of upside in generics, particularly of the branded, specialist kind.

You may also be interested in...



Entering The Generics Business In Mature Markets: Lessons Learned From 4,500 Launches

In response to major market challenges, Big Pharmas have or are considering entering the small-molecule generics business. An IMS Consulting Group analysis of more than 4,500 generics launches between 2005 and 2010 tracks key attributes would-be branded company players need to know for success.

Fourth Quarter Earnings Calls, In Brief

Vertex/FDA in discussions on “breakthrough therapies”; Ipsen earnings hurting in EU; Pfizer discusses biosimilars; Krka likes emerging markets; Novo sees GLP-1 market competition stiffening

Cinven's Mercury Pharma Buy Could Spur European Specialty Consolidation

Cinven’s $730 million acquisition of the U.K.-based specialty company Mercury Pharma could act as a platform to consolidate the sector in Europe, suggests the private equity company.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel